Saving the diabetic foot with special reference to the patient with chronic renal failure

Infectious Disease Clinics of North America

Volumn 15, Issue 3, 2001, Pages 953-981

  Deery II, H Gunner ^b   Sangeorzan, Jon A ^b  

^a Northern Michigan Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; CEFADROXIL; CEFALEXIN; CEFALOTIN; CEFAZOLIN; CEFRADINE; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; DICLOXACILLIN; GATIFLOXACIN; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METRONIDAZOLE; NAFCILLIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PLATELET DERIVED GROWTH FACTOR; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN SULFATE; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; CHRONIC KIDNEY FAILURE; CLINICAL EXAMINATION; DEBRIDEMENT; DIABETIC FOOT; EPIDEMIOLOGICAL DATA; FOOT AMPUTATION; HUMAN; HYPERBARIC OXYGEN; PATHOPHYSIOLOGY; REVIEW; VASCULAR SURGERY; WOUND CARE; WOUND DRESSING;

EID: 0034843651     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70179-3     Document Type: Article

References (130)

1. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration
2. Consensus development conference on diabetic foot wound care
3. Diabetic foot ulcers in a multidisciplinary setting: An economic analysis of primary healing and healing with amputation
4. Vacuum-assisted closure: A new method for wound control and treatment: Clinical experience
5. Evidence-based options for off-loading diabetic wounds
6. The edge effect: How and why wounds grow in size and depth
7. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration
8. Uremic neuropathy
9. The middle molecule hypothesis in perspective
10. Nephropathy and neuropathy
11. Contralateral limb and patient survival after leg amputation
12. Diabetic foot ulcers: A framework for prevention and care
13. The pathogenesis of diabetic foot problems: An overview
14. Hyperbaric oxygen therapy: A physiological approach to selected problem wound healing
15. A prospective study of risk factors for diabetic foot ulcer: The Seattle diabetic foot study
16. Office evaluation and management of the diabetic foot
17. Diabetic foot infections
18. Diabetic foot infections
19. The total contact cast: A method for treating neuropathic diabetic ulcers
20. Assessment and management of foot disease in patients with diabetes
21. Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers
22. New developments in the biomechanics of the diabetic foot
23. Antibiotic treatment for uncomplicated neuropathic foot ulcers in diabetes: A controlled trial
24. Large and small artery occlusions in diabetics and nondiabetics with severe vascular disease
25. Trial and error yields to knowledge
26. Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania
27. The use and abuse of wound care materials in the treatment of diabetic ulcerations
28. Atherogenic lipoprotein phenotype in endstage renal disease: Origin and extent of low-density lipoprotein formation
29. Hyperbaric oxygen therapy in diabetic foot
30. Occlusive dressings
31. Incidence of reamputation and death after gangrene of the lower extremity
32. Lower extremity amputation in diabetic patients
33. Limb salvage in end-stage renal disease
34. Nontraumatic lower-extremity amputations in the Medicare end-stage renal disease population
35. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer
36. Fourth Consensus Conference of the European Committee on Hyperbaric Medicine: Hyperbaric oxygen in the management of foot lesions in diabetic patients
37. Risk factors for non-ischemic foot ulceration in diabetic nephropathy
38. Reduction of gangrene and amputations in diabetic renal transplant patients: The role of a special foot clinic
39. Deterioration of diabetic foot lesions under hydrocolloid dressings
40. Role of neuropathy and high foot pressures in diabetic foot ulceration
41. Use of Dermagraft, a cultured human dermis to treat diabetic foot ulcers
42. Foot infections in diabetic patients: The role of anaerobes
43. Problems in diabetic foot care
44. The fate of the second leg in the diabetic amputee
45. Diabetic foot infections: Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases
46. Randomized placebo-controlled trial of granulocyte colony stimulating factor in diabetic foot infection
47. Diabetic foot infections: Antimicrobial therapy
48. The influence of renal function on diabetic foot ulceration
49. A review of wound healing and wound dressing products
50. Diabetes in America: Epidemiology and scope of the problem
51. Risk of foot complications in long-term diabetic patients with and without ESRD: A preliminary study
52. Recommendations for prevention of the spread of vancomycin resistance
53. Healing of wounds as determined by their tensile strength
54. The diabetic foot
55. Failure of foot salvage in patients with end-stage renal disease after surgical revascularization
56. Use of an anaerobic collection and transport swab devise to recover anaerobic bacteria from infected foot ulcers in diabetics
57. Selection of dressings for diabetic foot ulcers. The authors reply
58. Decreasing incidence of major amputation in diabetic patients: A consequence of a multidisciplinary foot care team approach?
59. Practical criteria for screening patients at high risk for diabetic foot ulceration
60. Microbiology of osteomyelitis in diabetic foot infections
61. Alginate dressings and the diabetic foot ulcer
62. The incidence of antimicrobial allergies in hospitalized patients
63. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers
64. Pathogenesis and management of diabetic foot lesions
65. Antibiotic therapy for diabetic foot infections: Comparison of two parenteral-to-oral regimens
66. Osteomyelitis of the foot in diabetic patients
67. Evidence-based antibiotic therapy of diabetic foot infections
68. Peripheral vascular disease in diabetes mellitus: Implications for surgical management
69. Vascular and microvascular disease of the diabetic foot: Implications for foot care
70. Trends in the care of diabetic foot: Expanded role of arterial reconstruction
71. Factors contributing to the presentation of diabetic foot ulcers
72. Update on the diagnosis and management of osteomyelitis
73. Hyperhomocystinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
74. Healing of diabetic neuropathic foot ulcers receiving standard treatment: A meta-analysis
75. Peripheral vascular disease in CAPD
76. A systemic review of foot ulcer in patients with type 2 diabetes mellitus, II: Treatment
77. Preventive foot care in people with diabetes
78. Recent commencement of dialysis is a risk factor for lower-extremity amputation in a high-risk diabetic population
79. Response to Rith-Najarian and Gohdes
80. Panel endorses Apligraf for diabetic foot ulcers, with several caveats
81. Diabetes related lower extremity amputations in New Jersey, 1979 to 1981
82. Effective treatment strategies for diabetic foot wounds
83. Maggot therapy for the treatment of diabetic foot ulcers
84. How effective is manual palpation in detecting subtle temperature differences?
85. The total-contact cast for management of neuropathic plantar ulceration of the foot
86. Peripheral vascular disease and diabetes
87. Effectiveness of a comprehensive diabetes lower-extremity amputation prevention program in a predominantly low-income African-American population
88. Pathways to diabetic limb amputation: Basis for prevention
89. Screening techniques to identify people at high risk for diabetic foot ulceration: A prospective multicenter trial
90. Peripheral neuropathy in patients with chronic renal failure. A treatable source of discomfort and disability
91. A human dermal replacement for the treatment of diabetic foot ulcers
92. Efficacy of the dorsal pedal bypass for limb salvage in diabetic patients: Short-term observations
93. Advanced glycation end products: A nephrologist's perspective
94. The burden of diabetic foot ulcers
95. Lower extremity ulcers and amputations in individuals with diabetes
96. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings
97. Risk factors for amputation in patients with diabetes mellitus
98. Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting
99. Preventing amputations among patients with diabetes on dialysis
100. Reducing lower-extremity amputations due to diabetes: Application of the staged diabetes management approach in a primary care setting
101. Wound infection: A failure of wound healing caused by an imbalance of bacteria
102. Wound healing alterations caused by infection
103. Healing alternatives
104. Hydrocolloid dressings require skill
105. Amputation of the lower extremity in diabetes mellitus
106. Total contact casting for diabetic neuropathic ulcers
107. Physiology and healing dynamics of chronic cutaneous wounds
108. Impediments to wound healing
109. Treatment with growth factors and skin equivalents
110. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo
111. The diabetic ulcer study group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers
112. Foundations of good ulcer care
113. Co-factors in impaired healing
114. Foot ulcers
115. Methicillin-resistant Staphylococcus aureus: An increasing problem in a diabetic foot clinic
116. Plantar pressure and plantar ulceration in the neuropathic diabetic foot
117. The dysvascular foot: A system of diagnosis and treatment
118. Diabetic nephropathy: Prevalence, complications and treatment
119. Hyperbaric oxygen in the treatment of diabetic foot lesions: Search for healing predictive factors
120. Hyperbaric oxygen therapy in chronic vascular wound management
121. The later life of the diabetic amputee
122. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: A phase III, randomized, placebo-controlled, double-blind study
123. Vascular rehabilitation: Benefits of a structured exercise/risk modification program
124. Formation of scab and the rate of epithelialization on superficial wounds in the skin of the domestic pig
125. Systemic hyperbaric oxygen therapy